Comparison of herceptest™ mab pharmdx (dako omnis, ge001) with ventana pathway anti-her-2/neu (4b5) in breast cancer: correlation with

HIGHLIGHTS

• who: Josef Rüschoff from the Targos, A Discovery Life Sciences Company, Germaniastraße, Kassel, Germany have published the Article: Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with, in the Journal: (JOURNAL)
• what: The authors report the results of an IHC concordance study comparing the HercepTest (mAb) run on the Dako Omnis platform and the PATHWAY 4B5 assay run on the Ventana BenchMark ULTRA using a BC cohort of 119 samples and assessing assay sensitivity and specificity with respect to amplification status . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.